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The aim of this study was to develop and validate a simple, rapid, precise, more accurate, reliable, least time 
consuming HPLC method for individual as well as simultaneous estimation of pravastatin, atorvastatin and 
simvastatin in bulk and pharmaceutical dosage form. The  chromatographic separation was achieved by using a 
mixture of methanol and 0.1 % orthophosphoric acid in water as the mobile phase, with  a C18 (150×4.6 mm i.d., 
2.7 µm) reversed-phase column at flow rate of 1.0 mL/min and the eluents were monitered at 238 nm. A good 
linearity was found in the 0.12-0.24 mg/mL for both pravastatin and atorvastatin and 0.02-0.14 mg/mL simvastatin 
concentration range. The accuracy was good and recovery values for pravastatin, atorvastatin and simvastatin 
ranged from 99.21-100.40%, 99.87-100.39 and 98.84-100.66%, respectively. The proposed novel method was found 
to be efficient, accurate, precise, specific and economic and is suitable for individually as well as simultaneous 
estimation in quality control laboratories and research institutes. 
 





The statins (or HMG-CoA reductase inhibitors) formed a class of hypolipidemic drugs used to lower cholesterol 
levels in people with or at risk of cardiovascular disease. Statins are effective and often-prescribed drugs for the 
treatment of lowering cholesterol and cardiovascular diseases. Pravastatin (PRV), Atrovastatin (ATV), Simvastatin 
(SIM) are the member of the statin [1-16] class of pharmaceutical drugs, for chemical structures see figure1. 
 
The primary uses of all these statins PRV, ATV, SIM is for the treatment of lowering cholesterol and the prevention 
of cardiovascular diseases. PRV acts as a lipoprotein-lowering drug. ATV is a competitive inhibitor of HMG-CoA 
reductase. SIM act by inhibiting 3-hydroxy-3-methylglutaryl coenzyme However, statins reduce cardiovascular 
disease and it works in lowering of cholesterol level. The aim of this study was to develop and validate a simple, 
rapid, precise, more accurate, reliable, least time consuming HPLC method for individually as well as simultaneous 
estimation of PRV, ATV and SIM  in bulk and pharmaceutical dosage form. The analytical method was validated 
[17-19] as per current International Conference on Harmonization (ICH) guidelines [20].   
 






























Apparatus and Chromatographic Conditions: Agilent 1200 series HPLC, G1331A Quaternary pump connected 
with G1314B Variable Wavelength detector, G1316A Thermostatted Column Compartment, G1329A ALS 
autosampler. The data acquisition was performed by Agilent Chemstation software. The chromatographic separation 
was performed using a Poroshell 120 SB C18 (150 mm×4.6 mm i.d., 2.7 µm particle size) column. Separation was 
achieved using a mobile phase consists of 0.1 % orthophosporic acid in water and methanol gradient elution mode, 
at a flow rate of 1 mL/min. The eluent was monitored using UV detection at a wavelength of 238 nm. The column 
temperature was maintained at 25 °C temperature and injection volume 5 µL was used. The total runtime was 15 
min. The mobile phase was filtered through 0.45 µm nylon membrane (Millipore) prior to use. 
 
Reagents: ortho phosphoric acid (AR grade, Spectrochem), methanol (HPLC grade, Thomas Baker), water (HPLC 
grade, Thomas Baker), PRA, ATV and SIM. 
 
Preparation of Mobile Phase: 
The mobile phase is composed of a mixture of methanol and 0.1% ortho phosphoric acid in water with gradient 
elution mode. The mobile phase were filtered separately through a 0.45 µm nylon membrane (Millipore) and 
degassed in an ultrasonic bath (Branson-5510) prior to use to avoid disturbances and column clogging due to small 
particles. Methanol used as diluent for standard and sample preparations. 
 
Gradient elution mode of mobile phase 
Time Mobile phase 
in min A % B % 
0 30 70 
4 20 80 
6 20 80 
8 10 90 
10 10 90 
12 30 70 
15 30 70 
 
Preparation of Standard Solution: 
The standard stock solution 1.0 mg/mL of both PRA, ATV and 0.5 mg/mL SIM was prepared in diluent. The 
working standard solution PRA, ATV (200 µg/mL) and SIM (100 µg/mL) was prepared by diluting the stock 
solution with diluent. The resulting solution was transferred to standard analytical HPLC glass vials and injected 
into the HPLC. 
 
Preparation of Sample Solution: 
To prepare a stock solution of sample, an accurately weighed amount, equivalent to 100 mg of both PRV, AVT and 
50 mg of SIM drugs from composite of 20 powdered tablets, was transferred into a 100 mL volumetric flask and 
dissolved in 50 mL of diluent and the mixture was sonicated for 30 min. The contents of the flask were then left to 
return to room temperature and volume was adjusted with the same solvent mixture and mixed well. This solution 
50 mL was filtered through a 0.45 µm nylon syringe filter. Pipette out 5 mL of above test stock solution and transfer 
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into 25 mL volumetric flask and dilute up to the mark with diluent. The concentration obtained is 200 µg/mL of 
PRV, ATV and 100 µg/mL of SIM of the test solution and injected to HPLC system for the analysis. All 
measurements were made at room temperature (25 ± 1°C) and 5 µL of clear solution was injected into HPLC system 
for the analysis. 
 
RESULTS AND DISCUSSION 
  
Method Development: 
This study was directed towards developing an RP-HPLC method for separation of statins like PRV, AVT and SIM 
and to determine assay in bulk and its pharmaceutical formulations. The aim of this study was to develop a rapid, 
more accurate, precise, reliable, least time consuming HPLC method for the three drugs individually as well as 
simultaneously. This analytical method was developed and validated in accordance with ICH guidelines. 
 
To optimize the operating conditions for RP-HPLC detection of all analytes, a number of parameters such as the 
mobile phase composition with different buffer solutions and the flow rate were varied. Various ratios of mobile 
phases like 60:40, 70:30, and 80:20 v/v of methanol: water was tested. The variation in the mobile phase leads to 
considerable changes in the chromatographic parameters, like peak symmetry, resolution and retention time. 
Orthophosporic acid was added to the mobile phase to optimize the peak shape with better resolution for all drugs 
analyzed with a detector wavelength 238 nm. The best peak shape and resolution were obtained when the mobile 
phase comprised of the methanol: water with orthophosphoric acid was used in the ratio of (70:30 v/v) in gradient 
elution mode at a flow rate of 1 mL/min. For simultaneous determination of PRV, ATV and SIM statin's drugs. A 
typical chromatogram obtained by using the aforementioned mobile phase from 5 µL of the assay preparation is 
illustrated in figure 2. The retention times of PRV, ATV and SIM were 3.646, 6.156 and 11.659 min, respectively. 
 
 
Figure 2: A typical chromatogram showing separation of statins like pravastatin (A), atorvastatin (B) and simvastatin (C). 
 
Accuracy and Precision: 
The accuracy of the method was studied by recovery experiments. The recovery experiments were performed by 
adding known amounts of the drug to the placebo. The recovery was determined at three levels, viz. 50 %, 100 % 
and 150 % of the selected concentrations. Three samples were prepared for each recovery level. The recovery values 
for PRV, ATV and SIM ranged from 99-101 %, 99-101 % and 98-101 %, respectively (table 1). The precision 
(repeatability and intermediate precision) of the method was determined from one lot of combined dosage form. 
Intra and Inter day studies were performed by taking six replicates of sample concentrations. The results are shown 
in table 2.  
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Table 1: Accuracy study of pravastatin, atorvastatin and simvastatin 
 
Parameter: Accuracy and Recovery 
Name Accuracy Level Amount added (mg/mL) Amount Recovered (mg/mL) Mean Recovery % RSD % 
PRV 
50 50.7 50.3 99.21 0.56 
100 100.4 100.8 100.40 0.28 
150 150.9 151.1 100.13 0.09 
ATV 
50 50.7 50.9 100.39 0.35 
100 100.4 100.6 100.20 0.14 
150 150.5 150.3 99.87 0.12 
SIM 
50 25.9 25.6 98.84 0.83 
100 50.2 49.8 99.20 0.57 
150 75.7 76.2 100.66 0.46 
 
Table 2: Precision study of pravastatin, atorvastatin and simvastatin 
 
Parameter : Precision 
Set PRV ATV SIM 






1 99.53 99.68 99.81 99.73 99.83 99.45 
2 99.26 99.51 99.75 99.56 99.78 99.59 
3 99.47 99.65 99.67 99.48 99.64 99.88 
4 99.56 99.58 99.83 99.37 99.76 99.55 
5 99.38 99.75 99.77 99.72 99.69 99.63 
6 99.59 99.57 99.83 99.69 99.83 99.83 
Mean 99.47 99.62 99.78 99.59 99.76 99.66 
SD 0.13 0.09 0.06 0.15 0.08 0.17 
RSD % 0.13 0.09 0.06 0.15 0.08 0.17 
 
System Suitability: 
The system suitability test ensures the validity of the analytical procedure as well as confirms the resolution between 
different peaks of interest. All critical parameters tested met the acceptance criteria on all days. The following 
system suitability criteria were fulfilled in the chromatograms- viz.,  % RSD of PRV, ATV and SIM were 0.40, 0.38 
and 1.05, resolution between the two peaks were greater than 2, tailing factor is between 0.9 - 2.0 and theoretical 
plates more than 2000. As shown in the chromatogram, all the analytes are eluted by forming symmetrical single 
peaks well separated from the solvent front. Results are tabulated in table 3. 
 
Table 3:  System suitability test results of pravastatin, atorvastatin and simvastatin 
 
Parameter: System suitability 
S. No. PRV ATV SIM 
 
RT Area RT Area RT Area 
1 3.628 1732.0 6.154 1656.9 11.640 1136.0 
2 3.601 1731.0 6.112 1660.5 11.614 1154.1 
3 3.583 1720.1 6.079 1654.3 11.598 1151.7 
4 3.576 1720.4 6.072 1645.7 11.594 1124.3 
5 3.585 1716.1 6.062 1645.0 11.562 1153.2 
6 3.570 1717.5 6.058 1649.4 11.588 1148.9 
Average 3.591 1722.9 6.090 1652.0 11.599 1144.7 
SD 0.021 6.898 0.037 6.277 0.026 11.992 
RSD % 0.59 0.40 0.61 0.38 0.23 1.05 
Tailing factor 
 
1.209 1.044 1.008 
Theoretical Plates 
 
14532 51162 229615 
Resolution 
 
- 21.813 53.289 
 
Linearity: 
The linearity of the method was tested from 0.12- 0.24 mg/mL for PRV, 0.12- 0.24 mg/mL for ATV and 0.02- 0.14 
mg/mL for SIM. Linearity solutions were injected in triplicate and the calibration graphs were plotted as peak area 
of the analyte against the concentration of the drug in mg/mL. In the simultaneous determination, the calibration 
graphs were found to be linear for both the analytes in the mentioned concentrations and the correlation coefficients 
for the regression line were 0.9997, 0.9996 and 0.9998 for PRV, ATV and MEL respectively see figure 3. 
 





Figure 3: Graph showing linearity and range of statins like pravastatin, atorvastatin and simvastatin 
 
Solution Stability: 
Stability studies were carried out by keeping the prepared sample solution at room temperature for 24 hours. The 
prepared sample solution was analyzed at different time intervals and found that the solution is stable. 
 
Robustness: 
The assay results were found to be unaffected by small changes in the chromatographic conditions like 
concentration of the mobile phase, flow rate and wavelength. 
 
Ruggedness: 
Ruggedness of the method was determined between two different analysts and instruments. The value of % RSD 
was < 2, tailing factor and the theoretical plates found to be well within the system suitability limits. This indicates 




Proposed study describes a new RP-HPLC method for the estimation of statins like PRV, ATV and SIM in bulk and 
pharmaceutical formulations using simple mobile phase with low buffer concentration compared to the reported 
method. The method gives good resolution between all the three statins with a short analysis time (<15 min). The 
method was validated and found to be simple, rapid, precise, more accurate, reliable, least time consuming HPLC 
method for three drugs individually as well as simultaneously. Percentage of recovery shows that the method is free 
from interference of the excipients used in the formulation and bulk material. Therefore, the proposed method can be 
used for routine analysis of PRV, ATV and SIM in quality control laboratories and research institutes. 
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